Karen Carey

Replidyne Raises $40M, Adds To Pipeline With Antibacterial Drug

Aug. 18, 2004

Replidyne Inc. closed its largest financing, a $40 million second round, and concurrently in-licensed a late-stage compound to treat bacterial infections. (BioWorld Today)

Halozyme Signs Baxter To Enhanze SC Marketing Deal

Aug. 17, 2004

By Karen Carey

Crucell Signs Up Another PER.C6 Customer, Enters Deal With GSK

Aug. 16, 2004

By Karen Carey

Enhance Merging With Ardent For Delta Receptor Compounds

Aug. 13, 2004

By Karen Carey

InSite Begins Phase III Trials Of AzaSite For Conjunctivitis

Aug. 12, 2004

By Karen Carey

Pharmasset Raises $40M In Series D For HIV Candidates

Aug. 11, 2004

By Karen Carey

Regeneron Secures License To Artemis Gene-Switch Technology

Aug. 10, 2004

By Karen Carey

DOV, Merck Partner In $455M Deal Focused On Depression

Aug. 9, 2004

By Karen Carey

DOV Pharmaceutical Inc. licensed worldwide rights of its triple uptake inhibitor compounds for psychiatric disorders to Merck & Co. Inc. in a deal worth $455 million, if all milestones are met. (BioWorld Today)